Division of Colon and Rectal Surgery, Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
ANZ J Surg. 2021 May;91(5):E286-E291. doi: 10.1111/ans.16547. Epub 2021 Jan 6.
Radiation therapy with concurrent chemotherapy is an important treatment for rectal cancer, especially for advanced stage disease. Low serum haemoglobin levels are accepted as a negative indicator in the response to radiation therapy. This study aimed to evaluate the relationship between anaemia and the response to preoperative chemoradiotherapy for rectal cancer and its effect on oncologic outcomes.
We retrospectively reviewed medical records of primary rectal cancer patients who were treated with preoperative chemoradiotherapy followed by total mesorectal excision between January 2011 and December 2015. Anaemia was defined as serum haemoglobin levels ≤9 g/dL before or during radiotherapy. Patients were divided into good and poor responders according to pathologic tumour regression grades. The effect of anaemia on the response to radiation therapy, recurrence-free survival and overall survival were analysed after subgroup analysis.
Overall, 301 and 394 patients were categorized into good and poor responder groups, respectively. Proportions of anaemia patients were higher in the poor responder group than in the good responder group (7.6% versus 4.0%, P = 0.042). Anaemia was associated with less pathologic complete regression but was not a risk factor for worse recurrence-free or overall survival. There was no significant difference in survival between patients with and without anaemia.
Haemoglobin levels ≤9 g/dL before or during radiotherapy were risk factors for achieving pathologic complete regression after preoperative chemoradiotherapy for rectal cancer. However, anaemia was not independently associated with worse survival outcomes.
同期放化疗是直肠癌的重要治疗方法,尤其是针对晚期疾病。血清血红蛋白水平低被认为是放射治疗反应的负面指标。本研究旨在评估贫血与直肠癌术前放化疗反应的关系及其对肿瘤学结果的影响。
我们回顾性分析了 2011 年 1 月至 2015 年 12 月期间接受术前放化疗后行全直肠系膜切除术的原发性直肠癌患者的病历。贫血定义为放疗前或放疗期间的血清血红蛋白水平≤9 g/dL。根据病理肿瘤消退分级将患者分为良好和不良反应者。在亚组分析后,分析贫血对放疗反应、无复发生存和总生存的影响。
总体而言,301 例和 394 例患者分别归入良好和不良反应组。不良反应组贫血患者比例高于良好反应组(7.6%比 4.0%,P=0.042)。贫血与较少的病理完全缓解有关,但不是无复发生存或总生存较差的危险因素。贫血患者与无贫血患者的生存无显著差异。
放疗前或放疗期间血红蛋白水平≤9 g/dL 是直肠癌术前放化疗后达到病理完全缓解的危险因素。然而,贫血与较差的生存结果无关。